Boehringer Ingelheim Roadshow - Product Launch!
Boehringer Ingelheim is introducing an exciting new treatment option for feline diabetes:
SENVELGO 15mg/l Oral Solution for Cats (velagliflozin) is a sodium glucose co-transporter 2 (SGLT2) inhibitor.
Boehringer Ingelheim is introducing an exciting new treatment option for feline diabetes:
SENVELGO 15mg/l Oral Solution for Cats (velagliflozin) is a sodium glucose co-transporter 2 (SGLT2) inhibitor.
The convenience of an oral once-daily solution is a game-changer for cats, cat owners and veterinarians.
Product highlights:
- once-daily oral solution; no needles
- no glucose curve monitoring
- sustained glycaemic control within one week with extremely low risk of clinical hypoglycaemia
- no dose titration; simple dose to cat’s weight
- room temperature; no refrigeration
The talk will cover:
- How SGLT2 inhibitors work
- Patient selection for Senvelgo
- What to expect when treatment starts
- What is involved in patient monitoring
Additionally we will discuss topics such as euglycemic DKA, switching cats already on insulin, options for ketone monitoring, diabetic remission, safety and side effects.
Boehringer Ingelheim supports the Australasian Diabetes Advisory Board, of which feline specialist Pru Galloway is a member, to provide veterinarians additional guidelines for patient selection and managing diabetic cats on Senvelgo.
Complimentary for NZVA and NZVNA members.